Skip to main content
. 2021 Nov 12;22(22):12273. doi: 10.3390/ijms222212273

Figure 5.

Figure 5

Umbellulone, the TRPA1 activator, promoted phosphorylation of SFKs at Y416, which was reduced by PKI (14–22) Amide, the PKA inhibitor, in the mouse TG. (A) Representative images showing Western blot analysis of expression of phosphorylated SFKs (pSFKs) at Y416, SFKs and β-actin in mouse TG treated by 0.06% DMSO (Veh), 600 μM umbellulone (UMB) or 600 μM umbellulone + 10 μM PKI (14–22) Amide (Myr-PKI); (B,C) data analysis of the expression levels of phosphorylated SFKs at Y1416 or SFKs relative to that of β-actin (absolute ratio in band intensity) and (D) comparison of relative pSFK/SFK levels (absolute ratio in band intensity) in mouse TG treated by 0.06% DMSO, 600 μM umbellulone or 600 μM umbellulone + 10 μM PKI (14–22) Amide (n = 8 per group). Group data were presented in as mean ± SEM. Two-tailed unpaired t-test was used for comparison between vehicle and umbellulone group, vehicle and PKI (14–22) Amide group in the presence of umbellulone. Significance differences were shown as * p < 0.05, ** p < 0.01, *** p < 0.001, or **** p < 0.0001.